Policy / Pricing Trump signs order to hasten psychedelic medicine access PharmaphorumDonald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.Policy / PricingNeuroscienceRead full story pharminent April 19, 2026 (Last updated: April 20, 2026) Pharmaphorum Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients. Policy / PricingNeuroscienceRead full story Post navigation Previous: Kailera makes history with record-breaking $625m IPONext: What actually drives speed in complex drug development programs Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
